




Instance: composition-en-37704f8130504ea382184950ae8a2cfe
InstanceOf: CompositionUvEpi
Title: "Composition for lokelma Package Leaflet"
Description:  "Composition for lokelma Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp67fbc8bafb10ece0b89924489b84bde8)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - lokelma"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Lokelma is and what it is used for</li>
<li>What you need to know before you take Lokelma</li>
<li>How to take Lokelma</li>
<li>Possible side effects</li>
<li>How to store Lokelma</li>
<li>Contents of the pack and other information</li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What lokelma is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What lokelma is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Lokelma contains the active substance sodium zirconium cyclosilicate. 
Lokelma is used to treat hyperkalaemia in adults. Hyperkalaemia means that there is a high level of 
potassium in the blood.
Lokelma lowers the high levels of potassium in your body and helps to keep it at a normal level. As 
Lokelma passes through your stomach and gut it attaches to potassium and the two are carried together 
out of the body in your stools, lowering the amount of potassium in the body.</p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take lokelma"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take lokelma"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Lokelma</p>
<p>If you are allergic to the active substance.
Warnings and precautions 
Monitoring
Your doctor or nurse will check your blood potassium level when you start taking this medicine:</p>
<p>This is to make sure you are getting the correct dose. The dose may be raised or lowered based 
on your blood potassium level.</p>
<p>Treatment may be stopped if your blood potassium level becomes too low.</p>
<p>Tell your doctor or nurse if you are taking any medicines which can change your blood 
potassium levels because your dose of Lokelma may need to be changed. These include
diuretics (medicines that increase urine production), angiotensin converting enzyme (ACE) 
inhibitors such as enalapril, angiotensin receptor blockers such as valsartan (medicines for high
blood pressure and for heart problems), and renin inhibitors such as aliskiren (for high blood
pressure).
While you are taking Lokelma, tell your doctor or nurse if</p>
<p>you have a heart signaling disorder (QT prolongation) since Lokelma lowers your blood 
potassium levels which may affect heart signaling. </p>
<p>you need to have an X-ray, as Lokelma may affect the interpretation of the results.</p>
<p>you have sudden or severe pain in your abdomen as this may be a sign of a problem that is 
observed with medicines that work in the gastrointestinal tract.
Children and adolescents
Do not give this medicine to children and adolescents under 18 years of age. This is because the 
effects of Lokelma in children and adolescents are not known.
Other medicines and Lokelma
Tell your doctor or nurse if you are taking, have recently taken or might take any other medicines.
Lokelma may affect how certain medicines are absorbed from your digestive tract. If you are taking 
any of the following medicines, they should be taken 2 hours before or after taking Lokelma, 
otherwise they may not work properly.</p>
<p>tacrolimus (medicines used to suppress your body s immune system to prevent organ transplant 
rejection)</p>
<p>ketoconazole, itraconazole and posaconazole (used to treat fungal infections)</p>
<p>atazanavir, nelfinavir, indinavir, ritonavir, saquinavir, raltegravir, ledipasvir and rilpivirine
(used to treat HIV infection)</p>
<p>tyrosine kinase inhibitors such as erlotinib, dasatinib and nilotinib (used to treat cancer)
If any of the above apply to you (or you are not sure), tell your doctor, pharmacist or nurse before 
taking this medicine.
Pregnancy and breast feeding
Pregnancy
Do not use this medicine during pregnancy because there is no information on its use in pregnancy.
Breast-feeding
No effects on the breastfed newborn/infant are anticipated since the systemic exposure of the breast-
feeding woman to Lokelma is negligible. Lokelma can be used during breast-feeding.
Driving and using machines
This medicine has no or negligible influence on your ability to drive or to use machines.
Lokelma contains sodium
This medicine contains approximately 400 mg sodium (main component of cooking/table salt) in each 
5 g dose. This is equivalent to 20% of the recommended maximum daily dietary intake of sodium for
an adult.
Talk to your pharmacist or doctor if you need Lokelma 5 g or more daily for a prolonged period, 
especially if you have been advised to follow a low salt (sodium) diet.</p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take lokelma"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take lokelma"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist 
if you are not sure.
How much to take
Starting dose - to lower your high potassium level to normal:</p>
<p>The recommended dose is 10 g taken three times a day.</p>
<p>The medicine takes one to two days to work.</p>
<p>Do not take this starting dose for more than three days.
Maintenance dose - to keep your potassium level within the normal range after it has been lowered:</p>
<p>The recommended dose is 5 g taken once a day.</p>
<p>Your doctor may decide that you need more (10 g once a day) or less than this (5 g every other 
day).</p>
<p>Do not take a maintenance dose of more than 10 g once a day.
If you are on haemodialysis therapy: </p>
<p>Take Lokelma only on non-dialysis days.</p>
<p>The recommended starting dose is 5 g taken once a day.</p>
<p>Your doctor may decide that you need more (up to 15 g once a day).</p>
<p>Do not take more than 15 g once a day.
Taking this medicine</p>
<p>Try to take Lokelma at the same time each day.</p>
<p>You can take this medicine with or without meal.
How to take</p>
<p>Open the sachet(s) and pour the powder into a drinking glass with approximately 45 ml of still 
(non-carbonated) water.</p>
<p>Stir well and drink the tasteless liquid straight away.</p>
<p>The powder does not dissolve and the liquid appears cloudy. The powder will settle in the glass 
quickly. If this happens, stir the liquid again and drink it all up.</p>
<p>If needed, rinse the glass with a small amount of water and drink it all up to take all the
medicine.
If you take more Lokelma than you should:
If you take more of this medicine than you should, talk to a doctor straight away. Do not take any 
more until you have spoken to a doctor.
If you forget to take Lokelma </p>
<p>If you forget to take a dose of this medicine, skip the missed dose.</p>
<p>Then take the next dose as usual at your normal time.</p>
<p>Do not take a double dose to make up for a forgotten dose.
If you stop taking Lokelma
Do not reduce the dose of this medicine or stop taking it without talking to the doctor who prescribed 
it. This is because you may get high potassium levels in your blood again.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.
Tell your doctor or nurse if you experience any of the following:
Common side effects (may affect up to 1 in 10 people).</p>
<p>you start to feel tired, or have muscle weakness or cramps, this may be a sign that your blood 
potassium has become too low. Talk to your doctor immediately if these symptoms become 
severe.</p>
<p>you start to have a build up of fluid in the tissues, leading to swelling anywhere in your body 
(usually in the feet and ankles).</p>
<p>constipation.
Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side 
effects not listed in this leaflet. You can also report side effects directly via the national reporting 
system listed in Appendix V. By reporting side effects you can help provide more information on the 
safety of this medicine.</p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store lokelma"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store lokelma"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton and the sachet after  EXP . 
The expiry date refers to the last day of that month.
This medicine does not require any special storage conditions.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment.</p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Lokelma contains 
The active substance is sodium zirconium cyclosilicate.
Lokelma 5 g powder for oral suspension
Each sachet contains 5 g of sodium zirconium cyclosilicate.
Lokelma 10 g powder for oral suspension
Each sachet contains 10 g of sodium zirconium cyclosilicate.
There are no other ingredients in this medicine.
What Lokelma looks like and contents of the pack
The powder for oral suspension is a white to grey powder. It comes in a sachet.
Lokelma 5 g powder for oral suspension
Each sachet contains 5 g of powder.
Lokelma 10 g powder for oral suspension
Each sachet contains 10 g of powder.
The sachets are supplied in a carton containing 3 or 30 sachets.
Not all pack sizes may be marketed. 
Marketing Authorisation Holder
AstraZeneca AB
SE-151 85 S dert lje
Sweden
Manufacturer
AstraZeneca AB
G rtunav gen
SE-152 57 S dert lje
Sweden
For any information about this medicine, please contact the local representative of the Marketing 
Authorisation Holder:
Belgi /Belgique/Belgien
AstraZeneca S.A./N.V.
Tel: +32 2 370 48 Lietuva
UAB AstraZeneca Lietuva
Tel: +370 5 2660 </p>
<p>.: +359 24455Luxembourg/Luxemburg
AstraZeneca S.A./N.V.
T l/Tel: +32 2 370 48  esk  republika
AstraZeneca Czech Republic s.r.o.
Tel: +420 222 807 Magyarorsz g
AstraZeneca Kft.
Tel.: +36 1 883 6Danmark
AstraZeneca A/S
Tlf: +45 43 66 64 Malta
Associated Drug Co. Ltd
Tel: +356 2277 8Deutschland
AstraZeneca GmbH
Tel: +49 40 809034Nederland
AstraZeneca BV
Tel: +31 85 808 9Eesti
AstraZeneca 
Tel: +372 6549 Norge
AstraZeneca AS
Tlf: +47 21 00 64<br />
AstraZeneca A.E.
 : +30 210 6871 sterreich
AstraZeneca  sterreich GmbH
Tel: +43 1 711 31 0
Espa a
AstraZeneca Farmac utica Spain, S.A.
Tel: +34 91 301 91 Polska
AstraZeneca Pharma Poland Sp. z o.o.
Tel.: +48 22 245 73 France
AstraZeneca
T l: +33 1 41 29 40 Portugal
AstraZeneca Produtos Farmac uticos, Lda.
Tel: +351 21 434 61 Hrvatska 
AstraZeneca d.o.o.
Tel: +385 1 4628 Rom nia
AstraZeneca Pharma SRL
Tel: +40 21 317 60 Ireland
AstraZeneca Pharmaceuticals (Ireland) Ltd
Tel: +353 1609 7Slovenija
AstraZeneca UK Limited
Tel: +386 1 51 35  sland
Vistor hf.
S mi: +354 535 7Slovensk  republika
AstraZeneca AB, o.z.
Tel: +421 2 5737 7Italia
AstraZeneca S.p.A.
Tel: +39 02 00704Suomi/Finland
AstraZeneca Oy
Puh/Tel: +358 10 23  </p>
<p>: +357 22490Sverige
AstraZeneca AB
Tel: +46 8 553 26 Latvija
SIA AstraZeneca Latvija
Tel: +371 67377United Kingdom (Northern Ireland)
AstraZeneca UK Ltd
Tel: +44 1582 836 This leaflet was last revised in
Other sources of information
Detailed information on this medicine is also available on the European Medicines Agency web site: 
http://www.ema.europa.eu</p>         </div>"""      



Instance: composition-da-37704f8130504ea382184950ae8a2cfe
InstanceOf: CompositionUvEpi
Title: "Composition for lokelma Package Leaflet"
Description:  "Composition for lokelma Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp67fbc8bafb10ece0b89924489b84bde8)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - lokelma"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen
1. Virkning og anvendelse 
2. Det skal du vide, før du begynder at tage Lokelma
3. Sådan skal du tage Lokelma
4. Bivirkninger
5. Opbevaring
6. Pakningsstørrelser og yderligere oplysninger</p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What lokelma is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What lokelma is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Lokelma indeholder det aktive stof natriumzirconiumcyclosilicat. 
Lokelma anvendes til behandling af hyperkaliæmi hos voksne. Hyperkaliæmi betyder, at blodet har et 
højt indhold af kalium.
Lokelma nedsætter det høje indhold af kalium i kroppen og hjælper med at opretholde et normalt 
niveau. Når Lokelma passerer gennem maven og tarmene, forbinder det sig med kalium, og de to
stoffer forlader kroppen sammen med afføringen. Hermed nedsættes indholdet af kalium i kroppen.</p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take lokelma"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take lokelma"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Lokelma

hvis du er allergisk over for det aktive stof.
Advarsler og forsigtighedsregler
Kontrol
Lægen eller sygeplejersken vil kontrollere indholdet af kalium i dit blod, når du starter med at tage 
dette lægemiddel:

Dette skal gøres for at sikre, at du får den korrekte dosis. Dosis kan sættes op eller ned, alt efter 
kaliumniveauet i dit blod.

Behandlingen kan blive stoppet, hvis kalium i blodet bliver for lavt.

Fortæl det til lægen eller sygeplejersken, hvis du tager lægemidler, der kan ændre indholdet af 
kalium i blodet, da din dosis af Lokelma måske skal ændres. Disse lægemidler omfatter 
vanddrivende lægemidler (diuretika - lægemidler, der øger produktionen af urin), 
angiotensinkonverterende enzym (ACE)-hæmmere, såsom enalapril, 
angiotensinreceptorblokkere såsom valsartan (lægemidler mod forhøjet blodtryk og 
hjerteproblemer) og reninhæmmere såsom aliskiren (mod forhøjet blodtryk).
27
Fortæl det til lægen eller sygeplejersken, at du tager Lokelma, hvis

du har en ledningsforstyrrelse i hjertet (QT-forlængelse), da Lokelma sænker kaliumniveauet i 
blodet, hvilket kan påvirke hjertets ledningssystem.

du skal have taget et røntgenbillede, da Lokelma kan påvirke tolkningen af billedet.

du får pludselige eller alvorlige smerter i maven, da dette kan være et tegn på en bivirkning, 
som ses med lægemidler, der virker i mave-tarm-kanalen.
Børn og unge
Du må ikke give dette lægemiddel til børn og unge under 18 år. Dette skyldes, at virkningen af 
Lokelma hos børn og unge ikke er kendt.
Brug af andre lægemidler sammen med Lokelma
Fortæl altid lægen eller sygeplejersken, hvis du tager andre lægemidler, for nylig har taget andre 
lægemidler eller planlægger at tage andre lægemidler.
Lokelma kan påvirke, hvordan visse lægemidler optages fra mave-tarm-kanalen. Hvis du tager nogle 
af følgende lægemidler, skal de tages 2 timer før eller efter, du tager Lokelma, da de ellers ikke vil 
virke korrekt.

tacrolimus (lægemiddel, der bruges til at undertrykke kroppens immunsystem for at forhindre 
afstødning af organtransplantater)

ketoconazol, itraconazol og posaconazol (til behandling af svampeinfektioner)

atazanavir, nelfinavir, indinavir, ritonavir, saquinavir, raltegravir, ledipasvir og rilpivirin (til 
behandling af hiv-infektion)

tyrosinkinasehæmmere såsom erlotinib, dasatinib og nilotinib (til behandling af cancer)
Fortæl det til lægen, apotekspersonalet eller sygeplejersken, inden du tager dette lægemiddel, hvis 
noget af ovenstående gælder for dig (eller hvis du er i tvivl).
Graviditet og amning
Graviditet
Du må ikke bruge dette lægemiddel, hvis du er gravid, da der ikke er nogen information om brug 
under graviditet.
Amning
Der forventes ingen påvirkning af nyfødte/spædbørn, som ammes, da den systemiske eksponering af 
den ammende kvinde for Lokelma er ubetydelig. Lokelma kan anvendes under amning.
Trafik- og arbejdssikkerhed
Lokelma påvirker ikke eller kun i ubetydelig grad evnen til at føre motorkøretøj og betjene maskiner.
Lokelma indeholder natrium
Dette lægemiddel indeholder ca. 400 mg natrium (hovedkomponent af madlavnings-/bordsalt) pr. 
dosis på 5 g. Dette svarer til 20 % af den anbefalede maksimale daglige indtagelse af natrium for en 
voksen.
Tal med apotekspersonalet eller lægen, hvis du i længere tid dagligt har brug for Lokelma 5 g eller 
derover, særligt hvis du er blevet bedt om at følge en saltfattig (natriumfattig) diæt.</p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take lokelma"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take lokelma"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens anvisning. Er du i tvivl, så spørg lægen eller
apotekspersonalet.
Så meget skal du tage
Startdosis  ̶ for at sænke dit høje niveau af kalium til det normale niveau:

Den anbefalede dosis er 10 g, som tages tre gange dagligt.
28

Lægemidlet skal tages en til to dage for at virke.

Tag ikke denne startdosis i mere end tre dage.
Vedligeholdelsesdosis  ̶  for at holde dit kaliumniveau inden for det normale, efter det er blevet nedsat:

Den anbefalede dosis er 5 g, som tages en gang dagligt.

Lægen kan afgøre, om du har brug for mere (10 g en gang dagligt) eller mindre end dette (5 g 
hver anden dag).

Du må ikke tage en højere vedligeholdelsesdosis end 10 g en gang dagligt.
Hvis du er i dialysebehandling:

Tag kun Lokelma på dage uden dialyse.

Den anbefalede startdosis er 5 g, som tages én gang dagligt.

Lægen kan beslutte, at du skal tage mere (op til 15 g én gang dagligt).

Du må ikke tage mere end 15 g én gang dagligt.
Indtagelse af lægemidlet

Forsøg at tage Lokelma på samme tidspunkt hver dag.

Du kan tage dette lægemiddel med eller uden et måltid.
Sådan tages lægemidlet

Åbn brevet (brevene), og hæld pulveret i et glas med ca. 45 ml postevand (uden brus).

Rør godt rundt, og drik straks den smagsløse væske.

Pulveret vil ikke blive opløst, og væsken ser uklar ud. Pulveret vil hurtigt lægge sig på bunden. 
Hvis dette sker, skal du omrøre væsken igen og drikke det hele. 

Skyl om nødvendigt glasset med lidt vand, og drik det hele for at få hele dosen af lægemidlet.
Hvis du har taget for meget Lokelma
Hvis du har taget mere af dette lægemiddel, end du skulle, skal du straks tale med en læge. Du må ikke 
tage mere, før du har talt med en læge.
Hvis du har glemt at tage Lokelma

Hvis du glemmer at tage en dosis af dette lægemiddel, skal du springe den glemte dosis over.

Tag derefter den næste dosis som sædvanligt på det normale tidspunkt.

Du må ikke tage en dobbeltdosis som erstatning for den glemte dosis.
Hvis du holder op med at tage Lokelma
Du må ikke nedsætte dosis eller stoppe med at tage lægemidlet uden først at have talt med den læge, 
der har udskrevet det. Dette skyldes, at du kan få et højt indhold af kalium i blodet igen.
Spørg lægen, apotekspersonalet eller sygeplejersken, hvis der er noget, du er i tvivl om.</p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger.
Fortæl det til lægen eller sygeplejersken, hvis du oplever noget af følgende:
Almindelige bivirkninger (kan forekomme hos op til 1 ud af 10 personer).

du begynder at føle dig træt, dine muskler bliver svage, eller du får muskelkramper; dette kan 
være et tegn på, at indholdet af kalium i dit blod er blevet for lavt. Fortæl det straks til din læge, 
hvis disse symptomer bliver alvorlige.

du begynder at ophobe væske i dine væv, hvilket medfører hævelser i hele kroppen (normalt i 
fødder og ankler).

forstoppelse.
Indberetning af bivirkninger
29
Hvis du oplever bivirkninger, bør du tale med din læge, apotekspersonalet eller sygeplejersken. Dette 
gælder også mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende 
kan også indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem 
anført i Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere 
information om sikkerheden af dette lægemiddel.</p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store lokelma"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store lokelma"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn.
Brug ikke lægemidlet efter den udløbsdato, der står på pakningen og brevet efter "EXP". 
Udløbsdatoen er den sidste dag i den nævnte måned.
Dette lægemiddel kræver ingen særlige forholdsregler vedrørende opbevaringen.
Spørg apotekspersonalet, hvordan du skal bortskaffe lægemiddelrester. Af hensyn til miljøet må du
ikke smide lægemiddelrester i afløbet, toilettet eller skraldespanden.</p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Lokelma indeholder:
Aktivt stof: natriumzirconiumcyclosilicat.
Lokelma 5 g pulver til oral suspension: 
Hvert brev indeholder 5 g natriumzirconiumcyclosilicat.
Lokelma 10 g pulver til oral suspension: 
Hvert brev indeholder 10 g natriumzirconiumcyclosilicat.
Der er ingen andre indholdsstoffer i dette lægemiddel.
Udseende og pakningsstørrelser
Pulveret til oral suspension er et hvidt til gråt pulver. Pulveret er indkapslet i et brev.
Lokelma 5 g pulver til oral suspension
Hvert brev indeholder 5 g pulver.
Lokelma 10 g pulver til oral suspension
Hvert brev indeholder 10 g pulver.
Brevene leveres i en karton, der indeholder 3 eller 30 breve.
Ikke alle pakningsstørrelser er nødvendigvis markedsført.
Indehaver af markedsføringstilladelsen
AstraZeneca AB
SE-151 85 Södertälje
Sverige
Fremstiller
AstraZeneca AB
Gärtunavägen
30
SE-152 57 Södertälje
Sverige
Hvis du ønsker yderligere oplysninger om dette lægemiddel, skal du henvende dig til den lokale 
repræsentant for indehaveren af markedsføringstilladelsen:
België/Belgique/Belgien
AstraZeneca S.A./N.V.
Tel: +32 2 370 48 11
Lietuva
UAB AstraZeneca Lietuva
Tel: +370 5 2660550
България
АстраЗенека България ЕООД
Тел.: +359 24455000
Luxembourg/Luxemburg
AstraZeneca S.A./N.V.
Tél/Tel: +32 2 370 48 11
Česká republika
AstraZeneca Czech Republic s.r.o.
Tel: +420 222 807 111
Magyarország
AstraZeneca Kft.
Tel.: +36 1 883 6500
Danmark
AstraZeneca A/S
Tlf: +45 43 66 64 62
Malta
Associated Drug Co. Ltd
Tel: +356 2277 8000
Deutschland
AstraZeneca GmbH
Tel: +49 40 809034100
Nederland
AstraZeneca BV
Tel: +31 85 808 9900
Eesti
AstraZeneca 
Tel: +372 6549 600
Norge
AstraZeneca AS
Tlf: +47 21 00 64 00
Ελλάδα
AstraZeneca A.E.
Τηλ: +30 210 6871500
Österreich
AstraZeneca Österreich GmbH
Tel: +43 1 711 31 0
España
AstraZeneca Farmacéutica Spain, S.A.
Tel: +34 91 301 91 00
Polska
AstraZeneca Pharma Poland Sp. z o.o.
Tel.: +48 22 245 73 00
France
AstraZeneca
Tél: +33 1 41 29 40 00
Portugal
AstraZeneca Produtos Farmacêuticos, Lda.
Tel: +351 21 434 61 00
Hrvatska 
AstraZeneca d.o.o.
Tel: +385 1 4628 000
România
AstraZeneca Pharma SRL
Tel: +40 21 317 60 41
Ireland
AstraZeneca Pharmaceuticals (Ireland) Ltd
Tel: +353 1609 7100
Slovenija
AstraZeneca UK Limited
Tel: +386 1 51 35 600
Ísland
Vistor hf.
Sími: +354 535 7000
Slovenská republika
AstraZeneca AB, o.z.
Tel: +421 2 5737 7Italia
AstraZeneca S.p.A.
Tel: +39 02 00704500
Suomi/Finland
AstraZeneca Oy
Puh/Tel: +358 10 23 010
31
Κύπρος
Αλέκτωρ Φαρµακευτική Λτδ
Τηλ: +357 22490305
Sverige
AstraZeneca AB
Tel: +46 8 553 26 000
Latvija
SIA AstraZeneca Latvija
Tel: +371 67377100
United Kingdom (Northern Ireland)
AstraZeneca UK Ltd
Tel: +44 1582 836 836
Denne indlægsseddel blev senest ændret
Andre informationskilder
Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs
hjemmeside http://www.ema.europa.eu.</p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-37704f8130504ea382184950ae8a2cfe
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for lokelma Package Leaflet for language en"
Description: "ePI document Bundle for lokelma Package Leaflet for language en"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-37704f8130504ea382184950ae8a2cfe"
* entry[0].resource = composition-en-37704f8130504ea382184950ae8a2cfe

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp37704f8130504ea382184950ae8a2cfe"
* entry[=].resource = mp37704f8130504ea382184950ae8a2cfe
                            
                    
Instance: bundlepackageleaflet-da-37704f8130504ea382184950ae8a2cfe
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for lokelma Package Leaflet for language da"
Description: "ePI document Bundle for lokelma Package Leaflet for language da"
Usage: #example




* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-37704f8130504ea382184950ae8a2cfe"
* entry[0].resource = composition-da-37704f8130504ea382184950ae8a2cfe

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp37704f8130504ea382184950ae8a2cfe"
* entry[=].resource = mp37704f8130504ea382184950ae8a2cfe
                            
                    



Instance: mp37704f8130504ea382184950ae8a2cfe
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product lokelma"
Description: "lokelma"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/17/1173/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"


* indication = "Lokelma is indicated for the treatment of hyperkalaemia in adult patients (see section 4.4 and 5.1)."


* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"


* name
  * productName = "lokelma"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#DK "DK"
    * jurisdiction = urn:iso:std:iso:3166#DK "DK"
    * language = urn:ietf:bcp:47#en  "en"




RuleSet: 37704f8130504ea382184950ae8a2cfeListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "lokelma"

* status = #current
* mode = #working

* title = "List of all ePIs associated with lokelma"

* subject = Reference(mp67fbc8bafb10ece0b89924489b84bde8)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#lokelma "lokelma"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-37704f8130504ea382184950ae8a2cfe) // lokelma en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-37704f8130504ea382184950ae8a2cfe) // lokelma da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-37704f8130504ea382184950ae8a2cfe
InstanceOf: List

* insert 37704f8130504ea382184950ae8a2cfeListRuleset
    